First Tracks Biotherapeutics Inc
NASDAQ:TRAXBiotechnology
-$0.89 today
- Market cap
- $1.83B
- Beta
- 0.00
- P/E (TTM)
- -6.1
- EPS (TTM)
- -$2.81
Volume 0.59M
Average 0.43M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
First Tracks Biotherapeutics Inc
NASDAQ:TRAX
Intrinsic Alpha fair value
Locked
Current Price
$43.57
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A — |
| Revenue | N/A | N/A | N/A | N/A — |
| Net Income | N/A | N/A | N/A | N/A — |
| EBIT | N/A | N/A | N/A | N/A — |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Immunovant, Inc. NASDAQ:IMVT | $7.07B | $34.18 | Not rated | -14.3 | +40.19% |
AnaptysBio, Inc. NASDAQ:ANAB | $1.38B | $46.25 | Overvalued | -59.7 | +84.88% |
MoonLake Immunotherapeutics NASDAQ:MLTX | $1.06B | $12.50 | Not rated | -5.4 | -16.04% |
Odyssey Therapeutics, Inc. NASDAQ:ODTX | $920.02M | $19.14 | Not rated | — | — |
Attovia Therapeutics, Inc. NASDAQ:ATTO | $691.63M | $15.13 | Not rated | -15.9 | — |
Aclaris Therapeutics, Inc. NASDAQ:ACRS | $621.76M | $3.92 | Not rated | -8.2 | +35.74% |
Climb Bio, Inc. NASDAQ:CLYM | $608.53M | $10.36 | Not rated | -14.7 | +412.04% |
SAB Biotherapeutics, Inc. NASDAQ:SABS | $266.66M | $2.96 | Not rated | 3.0 | -24.55% |
Eledon Pharmaceuticals, Inc. NASDAQ:ELDN | $171.87M | $2.12 | Not rated | -5.5 | +28.57% |
Immunic, Inc. NASDAQ:IMUX | $102.61M | $7.52 | Not rated | -4.1 | -3.55% |
Continue the stock analysis
Jump to another research area for this company.